Overview
Title
To require the Director of the National Institutes of Health to evaluate the results and status of completed and ongoing research related to menopause, perimenopause, or mid-life women’s health, to conduct and support additional such research, and for other purposes.
ELI5 AI
H.R. 6749 wants the National Institutes of Health to check how much we know about menopause and similar women's health issues, find out what's still unknown, and plan more research, all with the money they already have.
Summary AI
H.R. 6749, also called the “Menopause Research and Equity Act of 2023,” aims to have the Director of the National Institutes of Health (NIH) evaluate and report on completed and ongoing research related to menopause, perimenopause, and mid-life women's health. The bill requires the NIH to identify existing research gaps and propose a strategic plan with health professionals to address these issues. It also directs the Secretary of Health and Human Services to conduct or support further research on menopause and related health topics. This initiative will be carried out with the available budget, as no additional funds are authorized.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
The bill titled "Menopause Research and Equity Act of 2023," introduced in the House of Representatives on December 13, 2023, mandates that the Director of the National Institutes of Health (NIH) evaluate and expand research into menopause, perimenopause, and mid-life women's health. The act seeks to identify research gaps and allocate resources appropriately towards understanding and addressing these health issues more effectively.
General Summary
The primary aim of this legislative effort is to have the NIH conduct a thorough evaluation of completed and ongoing research related to menopause and related health conditions affecting women in mid-life. It also mandates compiling a strategic plan to address knowledge gaps and prioritize future research areas. Additionally, the act calls for further research on the causes, symptoms, and treatments of menopause and the impacts of hormonal treatment. This research is to be carried out without appropriating additional funds, relying instead on existing resources within the NIH's budget.
Significant Issues
Lack of Additional Funding: A major issue highlighted in the bill is the absence of new funding to support these initiatives, as outlined in Section 4. The expectation is that these efforts will be funded using existing NIH budget allocations. This raises concerns about potential reallocations from other important areas of research, potentially undermining other health priorities.
Budget and Spending Oversight: Section 2 of the bill does not specify budget limits for NIH's evaluation and research tasks, leading to concerns about unchecked spending. This absence of clear financial parameters could pose challenges given the potentially extensive scope of this research.
Ambiguity in Professional Involvement: The bill suggests forming a multidisciplinary group of health professionals to guide and develop research strategies; however, it lacks details on how these professionals will be selected. This omission raises potential concerns about bias or favoritism in this selection process.
Tight Reporting Timeline: The bill sets a 180-day deadline for NIH to submit an evaluation report and strategic plan to Congress, which might be seen as rushed. The feasibility of producing a comprehensive and accurate report in such a short timeframe may be questionable, potentially affecting the thoroughness of the analysis.
Impact on the Public
The bill's focus on menopause, perimenopause, and mid-life women's health underscores a commitment to addressing women's health issues more comprehensively, which could have positive implications for women's health on a national scale. As awareness and understanding of these conditions improve, it could lead to better health outcomes and healthcare practices for millions of women experiencing these transitions.
Impact on Specific Stakeholders
For women experiencing menopause and related health challenges, the bill has the potential for significant positive impact, potentially leading to improved health interventions and treatments. Healthcare providers may also benefit from clearer guidance and resources emerging from this research, enhancing their ability to treat patients effectively.
Conversely, stakeholders within the NIH and other research areas may face challenges due to the financial reallocation needed to comply with the bill’s mandates. Research on other health issues might experience funding and resource constraints if existing NIH funds are rechanneled towards menopause research without additional appropriations.
In summary, while the "Menopause Research and Equity Act of 2023" addresses critical gaps in women's health research with the intention of fostering improved understanding and treatment, concerns about funding, timeline, and process transparency remain significant. Addressing these concerns will be paramount in ensuring the legislation’s effective implementation and the equitable advancement of women's health research.
Issues
The lack of additional funds authorized to be appropriated in Section 4 raises concerns about how existing funds will be reallocated to support the initiatives outlined in the bill. This decision could lead to resource allocation challenges and potential shortfalls in other areas, which could be significant for both financial and operational reasons.
Section 2 does not specify a budget or spending limits for the evaluation and research efforts, potentially leading to unchecked spending without oversight. This absence of financial constraints could be significant given the scope of research implied.
Section 2 lacks specificity on how the multidisciplinary group of health professionals will be selected, causing potential concerns about favoritism, bias, or lack of representation in conducting the evaluations and developing strategies.
The mandate in Section 2 to submit a report and strategic plan within 180 days might be considered a tight timeline, potentially resulting in rushed conclusions or insufficient analysis, which raises political and operational concerns about the feasibility of such timelines.
The absence of clear guidance on using existing funds as outlined in Section 4 may lead to ethical concerns about redirecting funds from other potentially critical research or health initiatives, impacting other areas of health research or services.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The first section of the Act provides the short title, stating that it may be called the “Menopause Research and Equity Act of 2023.”
2. Evaluation of completed and ongoing research related to menopause, perimenopause, or mid-life women’s health Read Opens in new tab
Summary AI
The Director of the National Institutes of Health is tasked with evaluating both completed and ongoing research on menopause, perimenopause, or mid-life women’s health, identifying knowledge gaps and research funding over the last five years. Additionally, a report and strategic plan must be submitted to Congress within 180 days, which will include collaboration with health professionals to address research gaps and prioritize future research topics.
3. Additional research related to menopause, perimenopause, or mid-life women’s health Read Opens in new tab
Summary AI
The bill requires the Secretary of Health and Human Services, through the National Institutes of Health, to conduct or fund research about menopause and women's health in mid-life, focusing on understanding causes, symptoms, treatments, and the effects of hormonal treatments.
4. No additional funds authorized to be appropriated Read Opens in new tab
Summary AI
No extra funds will be allocated for this section; it must be carried out with the currently available budget.